Docket Number:10A-960116
Inventor:Han-Chung Wu, Chin-Tarng Lin, De-Kuan Chang
IP Status:US8415453
Abstract:
Lung cancer is the leading cause of cancer-related mortality in the world. The five-year survival rate is less than 15 % for patients with advanced non-small cell lung cancer (NSCLC). Conventional chemotherapy is limited by the toxicity of the drugs to normal tissues. We have identified a novel peptide capable of binding to several NSCLC cell lines but not able to bind to normal cells. The targeting peptide is able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, this targeting peptide significantly improves the therapeutic index of drug to NSCLC.
Fields of Application:
Targeting therapy and drug delivery system of NSCLC Diagnosis of NSCLC .
Advantages when compared to the existing technologies:
Lack of tumor specificity remains a major problem for chemotherapies in which side effects prevent the delivery of the drug dosages needed to eliminate the majority of cancer cells. Targeting peptide coupled to liposomes containing anti-cancer drugs vinorelbine or doxorubicin, significantly improved drug efficacy against human lung cancer xenografts and reduced drug toxicity.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you.
